Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

• Published in: European heart journal Vol. 36; no. 20; pp. 1264 - 1272
• Main Authors: Held, Claes, Hylek, Elaine M, Alexander, John H, Hanna, Michael, Lopes, Renato D, Wojdyla, Daniel M, Thomas, Laine, Al-Khalidi, Hussein, Alings, Marco, Xavier, Dennis, Ansell, Jack, Goto, Shinya, Ruzyllo, Witold, Rosenqvist, Mårten, Verheugt, Freek W A, Zhu, Jun, Granger, Christopher B, Wallentin, Lars
• Format: Journal Article
• Language: English
• Published: England 21.05.2015
• Subjects: Atrial Fibrillation - complications; Atrial Fibrillation - mortality; Factor Xa Inhibitors - administration & dosage; Factor Xa Inhibitors - adverse effects; Female; Follow-Up Studies; Hemorrhage - chemically induced; Hemorrhage - mortality; Humans; Intracranial Hemorrhages - chemically induced; Intracranial Hemorrhages - mortality; Male; Medicin och hälsovetenskap; Middle Aged; Myocardial Infarction - etiology; Myocardial Infarction - mortality; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyridones - administration & dosage; Pyridones - adverse effects; Stroke - mortality; Stroke - prevention & control; Thromboembolism - mortality; Thromboembolism - prevention & control; Treatment Outcome; Warfarin - administration & dosage; Warfarin - adverse effects; Atrial fibrillation; Bleeding; Factor Xa inhibitor
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehu463

In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of stroke, major bleed, and death in patients with atrial fibrillation. In this ancillary study, we evaluated clinical consequences of major bleeds, as well as management and treatment effects of warfarin vs. apixaban. Major International Society on Thrombosis and Haemostasis bleeding was defined as overt bleeding accompanied by a decrease in haemoglobin (Hb) of ≥2 g/dL or transfusion of ≥2 units of packed red cells, occurring at a critical site or resulting in death. Time to event [death, ischaemic stroke, or myocardial infarction (MI)] was evaluated by Cox regression models. The excess risk associated with bleeding was evaluated by separate time-dependent indicators for intracranial (ICH) and non-intracranial haemorrhage. Major bleeding occurred in 848 individuals (4.7%), of whom 126 (14.9%) died within 30 days. Of 176 patients with an ICH, 76 (43.2%) died, and of the 695 patients with major non-ICH, 64 (9.2%) died within 30 days of the bleeding. The risk of death, ischaemic stroke, or MI was increased roughly 12-fold after a major non-ICH bleeding event within 30 days. Corresponding risk of death following an ICH was markedly increased, with HR 121.5 (95% CI 91.3-161.8) as was stroke or MI with HR 21.95 (95% CI 9.88-48.81), respectively. Among patients with major bleeds, 20.8% received vitamin K and/or related medications (fresh frozen plasma, coagulation factors, factor VIIa) to stop bleeding within 3 days, and 37% received blood transfusion. There was no interaction between apixaban and warfarin and major bleeding on the risk of death, stroke, or MI. Major bleeding was associated with substantially increased risk of death, ischaemic stroke, or MI, especially following ICH, and this risk was similarly elevated regardless of treatment with apixaban or warfarin. These results underscore the importance of preventing bleeding in anti-coagulated patients. ClinicalTrials.gov Identifier: NCT00412984.